Lupus Nephritis Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034

The Lupus Nephritis market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Hoffmann-La Roche, Chugai Pharmaceutical, Novartis Pharmaceuticals, RemeGen Co., Ltd., argenx, AstraZeneca, Jiangsu Renocell Biotech Company, Qilu Pharmaceutical Co., Ltd., Genovate Biotechnology Co., Ltd.,, BeiGene, Astellas Pharma China, Inc., Aurinia Pharmaceuticals Inc., Boehringer Ingelheim, Nippon Kayaku Co., Ltd., Genentech, Inc.

[Nevada, United States] - DelveInsight's "Lupus Nephritis Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Lupus Nephritis, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Lupus Nephritis Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/report-store/lupus-nephritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Lupus Nephritis Market Report:
The Lupus Nephritis market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
In October, 2024: Hoffmann-La Roche announced that a phase II, randomized, double-blind, placebo-controlled study is designed to evaluate the safety, efficacy and pharmacokinetics (PK) of obinutuzumab in adolescent participants (AP) aged 12 to less than 18 with biopsy-confirmed proliferative lupus nephritis (LN).
In October, 2024: Novartis Pharmaceuticals announced that the purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) versus Standard of Care (SOC) in patients with systemic lupus erythematosus (SLE) with active, refractory lupus nephritis (LN).
In October, 2024: Alexion Pharmaceuticals, Inc. announced that a Phase 2, randomized, double-blind, placebo-controlled, multicenter study of ALXN2050 (120 and 180 milligrams [mg]) in addition to background therapy consistent with the standard of care in adult participants (≥ 18 to ≤ 75 years of age) with either LN or IgAN.
In September, 2024: RemeGen Co., Ltd. announced that a phase 2, multicentre, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of telitacicept versus placebo while taking standard of care (SOC) treatment in adult subjects with active proliferative lupus nephritis (LN).
In September, 2024: AstraZeneca announced that the purpose of this study is to evaluate the efficacy and safety of IV antifrolumab in adult patients with Active Proliferative Lupus Nephritis
Key Lupus Nephritis Companies are as follows: Hoffmann-La Roche, Chugai Pharmaceutical, Novartis Pharmaceuticals, RemeGen Co., Ltd., argenx, AstraZeneca, Jiangsu Renocell Biotech Company, Qilu Pharmaceutical Co., Ltd., Genovate Biotechnology Co., Ltd.,, BeiGene, Astellas Pharma China, Inc., Aurinia Pharmaceuticals Inc., Boehringer Ingelheim, Nippon Kayaku Co., Ltd., Genentech, Inc.
Key Lupus Nephritis Therapies are as follow: Telitacicept, efgartigimod, Anifrolumab, ianalumab, Voclosporin, Zanubrutinib, Voclosporin, Tacrolimus, Obinutuzumab, Mycophenolate, BI 655064, NKT-01, tacrolimus, Mizoribine, Cyclophosphamide, Rituximab, KZR-616
Launching multiple stage Lupus Nephritis pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Lupus Nephritis market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/sample-request/lupus-nephritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Lupus Nephritis Overview:
Lupus nephritis (LN) is a severe inflammation of the kidneys caused by Systemic Lupus Erythematosus (SLE), an autoimmune disorder where the immune system attacks healthy tissues. This kidney inflammation leads to the loss of kidney function, proteinuria (excess protein in urine), and if left untreated, can result in end-stage renal disease (ESRD). Lupus nephritis affects nearly half of all lupus patients at some point during the disease.

Lupus Nephritis Epidemiology Segmentation:
The Lupus Nephritis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
Lupus Nephritis Total Diagnosed Prevalent Cases
Lupus Nephritis Total Prevalent Cases
Lupus Nephritis Gender-specific Prevalence
Lupus Nephritis Diagnosed Cases of Episodic and Chronic

For more information about Lupus Nephritis companies working in the treatment market, visit https://www.delveinsight.com/sample-request/lupus-nephritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Lupus Nephritis Market Insights
The lupus nephritis market is expected to grow at a compound annual growth rate (CAGR) of 6-8% over the next few years, with an estimated market value surpassing $2 billion by 2030.
North America leads the market, followed by Europe, due to higher awareness, better healthcare infrastructure, and strong patient support networks. However, emerging markets in Asia-Pacific and Latin America are witnessing significant growth due to rising diagnosis rates and improved access to treatments
Major pharmaceutical companies active in the lupus nephritis market include GlaxoSmithKline, AstraZeneca, Roche, Biogen, Bristol Myers Squibb, and Eli Lilly, which are focusing on developing new biologics and expanding the indications for existing drugs.
Lupus Nephritis Drugs Uptake
Belimumab (Benlysta): Approved by the U.S. FDA in 2020 as the first biologic for lupus nephritis, Belimumab targets B-lymphocyte stimulator (BLyS), reducing B-cell activity that contributes to lupus. It has shown efficacy in reducing disease activity and the need for corticosteroids.
Rituximab: Though not formally approved for lupus nephritis, this anti-CD20 monoclonal antibody is used off-label to deplete B-cells, particularly in patients with refractory disease.
Voclosporin (Lupkynis): Approved by the FDA in 2021, voclosporin is a novel calcineurin inhibitor that reduces inflammation and protects kidney function in patients with lupus nephritis. Its favorable safety profile and ability to improve long-term outcomes have contributed to increased uptake.

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/lupus-nephritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Lupus Nephritis Therapies and Key Companies:
Telitacicept: RemeGen Co., Ltd.
efgartigimod: argenx
Anifrolumab: AstraZeneca
ianalumab: Novartis Pharmaceuticals
Voclosporin: Qilu Pharmaceutical Co., Ltd
Zanubrutinib: BeiGene
Voclosporin: Aurinia Pharmaceuticals Inc.
Tacrolimus: Astellas Pharma China, Inc.
Obinutuzumab, Mycophenolate: Hoffmann-La Roche
BI 655064: Boehringer Ingelheim
NKT-01: Nippon Kayaku Co., Ltd.
tacrolimus: Astellas Pharma Inc
Mizoribine, Cyclophosphamide: Asahi Kasei Pharma Corporation
Rituximab: Genentech, Inc.
KZR-616: Kezar Life Sciences, Inc.

Lupus Nephritis Epidemiology:
The epidemiology section provides insights into historical, current, and forecasted trends in the seven major countries (7MM) from 2020 to 2034. It explores various studies and opinions to recognize the causes of current and forecasted trends. The segmentation includes total prevalence, severity-based prevalence, gender-specific prevalence, and diagnosed cases of episodic and chronic Lupus Nephritis.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/lupus-nephritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Lupus Nephritis Market Drivers:
Growing Disease Prevalence
Novel Therapeutic Approaches
Increased Research and Development
Favorable Regulatory Environment

Lupus Nephritis Market Barriers:
High Cost of Biologic Therapies
Delayed Diagnosis and Underdiagnosis
Side Effects and Long-term Safety Concerns
Lack of Awareness in Developing Regions

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/lupus-nephritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Lupus Nephritis Market Report:
Study Period: 2020-2034
Coverage: 7MM (The United States, EU5, and Japan)
Key Lupus Nephritis Companies: Hoffmann-La Roche, Chugai Pharmaceutical, Novartis Pharmaceuticals, RemeGen Co., Ltd., argenx, AstraZeneca, Jiangsu Renocell Biotech Company, Qilu Pharmaceutical Co., Ltd., Genovate Biotechnology Co., Ltd.,, BeiGene, Astellas Pharma China, Inc., Aurinia Pharmaceuticals Inc., Boehringer Ingelheim, Nippon Kayaku Co., Ltd., Genentech, Inc.
Key Lupus Nephritis Therapies: Telitacicept, efgartigimod, Anifrolumab, ianalumab, Voclosporin, Zanubrutinib, Voclosporin, Tacrolimus, Obinutuzumab, Mycophenolate, BI 655064, NKT-01, tacrolimus, Mizoribine, Cyclophosphamide, Rituximab, KZR-616
Lupus Nephritis Therapeutic Assessment: Current marketed and emerging therapies
Lupus Nephritis Market Dynamics: Lupus Nephritis Market drivers and Lupus Nephritis barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Lupus Nephritis Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Lupus Nephritis market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/sample-request/lupus-nephritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1. Key Insights
2. Report Introduction
3. Lupus Nephritis Market Overview at a Glance
4. Executive Summary of Lupus Nephritis
5. Key Events
6. Epidemiology and Market Forecast Methodology
7. Disease Background and Overview
8. Current Treatment Practices of Lupus Nephritis
9. Patient Journey
10. Epidemiology and Patient Population
11. Marketed Therapies
12. Emerging Therapies
13. Lupus Nephritis: Seven Major Market Analysis
14. Unmet Needs
15. SWOT Analysis
16. KOL Views
17. Market Access and Reimbursement
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.